Jules Bordet Institute registers Phase 2 scalp cooling trial for ADC-related hair lossNov 16Trial updateGilead Sciencessacituzumab govitecan
ALX Oncology reports Q3 2026 results, sets December data for ALX2004Nov 16Quarterly updateALX Oncology Inc.
Seagen/Pfizer's MOUNTAINEER-03 trial for HER2+ colorectal cancer remains active, not recruitingNov 16Trial updatebevacizumabPfizer
The company: FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancerNov 12Regulatory decisionpertuzumab-dpzbpertuzumab, trastuzumab, and hyaluronidase-zzxfRecord notice
FDA approves Biocon Biologics' Pebrilzo, a pertuzumab productNov 12Regulatory decisionBioconpertuzumab, trastuzumab, and hyaluronidase-zzxf
Boehringer posts BI 1291583 results; registers obrixtamig rollover and four more trialsNov 12Weekly roundup, 7 itemsBoehringer IngelheimzongertinibUpdated
FDA accelerated approval for Enhertu in HER2-positive solid tumors, dated April 5, 2024Nov 9Regulatory decisionAmgenDaiichi Sankyo
Zymeworks raises 2026 guidance after $250M Ziihera milestone, posts Roche deal for ZW209Nov 9Quarterly updateJazz PharmaceuticalsRoche
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
AstraZeneca's FORTUNA misses in NASH as ARTEMIS kidney trial ends for lack of efficacyOct 30Weekly roundup, 8 itemsalbuterol sulfate and budesonideAstraZenecaUpdated
Enhertu wins EU approval for adjuvant HER2-positive early breast cancerOct 27Regulatory decisionAstraZenecaDaiichi Sankyo
Daiichi Sankyo registers Phase 3b T-DXd sequencing trial; posts RWE and access-program studiesOct 16Weekly roundup, 3 itemsAstraZenecaDaiichi Sankyo
FDA approves tucatinib combo for HER2-positive breast cancer maintenanceOct 7Regulatory decisionPfizertucatinib
CHMP backs two AstraZeneca drugs: Klygefa in gMG, Enhertu in early breast cancerSep 21Regulatory milestoneAstraZenecafam-trastuzumab deruxtecan-nxki
EU clears Enhertu plus pertuzumab as first-line HER2-positive metastatic breast cancer therapyAug 31Regulatory decisionAstraZenecafam-trastuzumab deruxtecan-nxki
FDA approves Ziihera-based regimens for first-line HER2+ gastroesophageal cancerAug 25Regulatory decisionBeiGeneJazz Pharmaceuticals
BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 resultsAug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.
BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trialsAug 11Quarterly updateBridgeBio Oncology Therapeutics, Inc.
ALX Oncology posts Q2 2026 results, reaffirms mid-2027 ASPEN-09-Breast readoutAug 6Quarterly updateALX Oncology Inc.
BeOne Medicines reports Q2 2026 results, raises full-year revenue guidanceAug 5Quarterly updateBeiGenesonrotoclax
Ocrevus higher-dose Phase 3 posts results, misses primary endpoint; two partner trials updateJul 24Weekly roundup, 4 itemsobinutuzumabocrelizumab
Merck completes MK-4082 obesity pill PK study; adds V132 vaccine and belzutifan pediatric trialsJul 17Weekly roundup, 8 itemsbelzutifanDaiichi Sankyo
AstraZeneca posts NATRON Phase III benralizumab results; registers ROSY-S anifrolumab rollover studyJul 10Weekly roundup, 9 itemsanifrolumab-fniaAstraZeneca
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
Novartis: Mayzent label update approved; four real-world studies registered or recruitingJul 2Weekly roundup, 7 itemsalpelisibFludarabine
EU approves Enhertu as first tumor-agnostic HER2-directed ADCJun 29Regulatory decisionAstraZenecafam-trastuzumab deruxtecan-nxki